Janssen, a Johnson & Johnson company, has announced positive topline results from its Phase 2b FRONTIER 1 trial evaluating JNJ-2113, a novel first-and-only oral interleukin-23 receptor antagonist ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results